Daxor Corporation (DXR) Stock Competitors & Peer Comparison
See (DXR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DXR | $10.38 | +0.29% | 52.3M | 27.15 | $0.38 | N/A |
| BDX | $158.08 | +3.39% | 57.3B | 11.75 | $13.45 | +2.37% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.37% |
| MDLN | $43.19 | +3.50% | 36.5B | 50.22 | $0.86 | N/A |
| WST | $365.74 | +0.20% | 25.8B | 45.89 | $7.97 | +0.24% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $74.20 | +3.13% | 14.5B | 16.27 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.37% |
| BAX | $22.65 | +4.43% | 11.7B | 10.89 | $2.08 | +0.88% |
| ATR | $126.98 | +1.38% | 8.1B | 22.20 | $5.72 | +1.49% |
Stock Comparison
DXR vs BDX Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, BDX has a market cap of 57.3B. Regarding current trading prices, DXR is priced at $10.38, while BDX trades at $158.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas BDX's P/E ratio is 11.75. In terms of profitability, DXR's ROE is +0.22%, compared to BDX's ROE of +0.05%. Regarding short-term risk, DXR is less volatile compared to BDX. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check BDX's competition here
DXR vs BDXA Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, DXR is priced at $10.38, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas BDXA's P/E ratio is 45.70. In terms of profitability, DXR's ROE is +0.22%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, DXR is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check BDXA's competition here
DXR vs MDLN Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, MDLN has a market cap of 36.5B. Regarding current trading prices, DXR is priced at $10.38, while MDLN trades at $43.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas MDLN's P/E ratio is 50.22. In terms of profitability, DXR's ROE is +0.22%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, DXR is less volatile compared to MDLN. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check MDLN's competition here
DXR vs WST Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, WST has a market cap of 25.8B. Regarding current trading prices, DXR is priced at $10.38, while WST trades at $365.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas WST's P/E ratio is 45.89. In terms of profitability, DXR's ROE is +0.22%, compared to WST's ROE of +0.18%. Regarding short-term risk, DXR is less volatile compared to WST. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check WST's competition here
DXR vs HOLX Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, DXR is priced at $10.38, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas HOLX's P/E ratio is 31.54. In terms of profitability, DXR's ROE is +0.22%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, DXR and HOLX have similar daily volatility (0.00).Check HOLX's competition here
DXR vs COO Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, COO has a market cap of 14.5B. Regarding current trading prices, DXR is priced at $10.38, while COO trades at $74.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas COO's P/E ratio is 16.27. In terms of profitability, DXR's ROE is +0.22%, compared to COO's ROE of +0.03%. Regarding short-term risk, DXR is less volatile compared to COO. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check COO's competition here
DXR vs BDXB Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, DXR is priced at $10.38, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas BDXB's P/E ratio is 7.60. In terms of profitability, DXR's ROE is +0.22%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, DXR is less volatile compared to BDXB. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check BDXB's competition here
DXR vs BAX Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, BAX has a market cap of 11.7B. Regarding current trading prices, DXR is priced at $10.38, while BAX trades at $22.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas BAX's P/E ratio is 10.89. In terms of profitability, DXR's ROE is +0.22%, compared to BAX's ROE of -0.16%. Regarding short-term risk, DXR is less volatile compared to BAX. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check BAX's competition here
DXR vs ATR Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, ATR has a market cap of 8.1B. Regarding current trading prices, DXR is priced at $10.38, while ATR trades at $126.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas ATR's P/E ratio is 22.20. In terms of profitability, DXR's ROE is +0.22%, compared to ATR's ROE of +0.14%. Regarding short-term risk, DXR is less volatile compared to ATR. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ATR's competition here
DXR vs RGEN Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, RGEN has a market cap of 8B. Regarding current trading prices, DXR is priced at $10.38, while RGEN trades at $142.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas RGEN's P/E ratio is 79.11. In terms of profitability, DXR's ROE is +0.22%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, DXR is less volatile compared to RGEN. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check RGEN's competition here
DXR vs AVTR Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, AVTR has a market cap of 7B. Regarding current trading prices, DXR is priced at $10.38, while AVTR trades at $10.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas AVTR's P/E ratio is 12.14. In terms of profitability, DXR's ROE is +0.22%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, DXR is less volatile compared to AVTR. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check AVTR's competition here
DXR vs BLCO Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, BLCO has a market cap of 6.1B. Regarding current trading prices, DXR is priced at $10.38, while BLCO trades at $17.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas BLCO's P/E ratio is 26.40. In terms of profitability, DXR's ROE is +0.22%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, DXR is less volatile compared to BLCO. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check BLCO's competition here
DXR vs TFX Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, TFX has a market cap of 5.9B. Regarding current trading prices, DXR is priced at $10.38, while TFX trades at $133.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas TFX's P/E ratio is 12.50. In terms of profitability, DXR's ROE is +0.22%, compared to TFX's ROE of -0.28%. Regarding short-term risk, DXR is less volatile compared to TFX. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check TFX's competition here
DXR vs STVN Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, STVN has a market cap of 5.2B. Regarding current trading prices, DXR is priced at $10.38, while STVN trades at $19.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas STVN's P/E ratio is 30.65. In terms of profitability, DXR's ROE is +0.22%, compared to STVN's ROE of +0.10%. Regarding short-term risk, DXR is less volatile compared to STVN. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check STVN's competition here
DXR vs MMSI Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, MMSI has a market cap of 4.2B. Regarding current trading prices, DXR is priced at $10.38, while MMSI trades at $71.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas MMSI's P/E ratio is 18.18. In terms of profitability, DXR's ROE is +0.22%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, DXR is less volatile compared to MMSI. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check MMSI's competition here
DXR vs ICUI Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, DXR is priced at $10.38, while ICUI trades at $154.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas ICUI's P/E ratio is 19.35. In terms of profitability, DXR's ROE is +0.22%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, DXR is less volatile compared to ICUI. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ICUI's competition here
DXR vs WRBY Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, WRBY has a market cap of 3.6B. Regarding current trading prices, DXR is priced at $10.38, while WRBY trades at $29.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas WRBY's P/E ratio is 108.37. In terms of profitability, DXR's ROE is +0.22%, compared to WRBY's ROE of +0.00%. Regarding short-term risk, DXR is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check WRBY's competition here
DXR vs HAE Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, HAE has a market cap of 3.4B. Regarding current trading prices, DXR is priced at $10.38, while HAE trades at $75.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas HAE's P/E ratio is 15.10. In terms of profitability, DXR's ROE is +0.22%, compared to HAE's ROE of +0.11%. Regarding short-term risk, DXR is less volatile compared to HAE. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check HAE's competition here
DXR vs LMAT Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, LMAT has a market cap of 2.4B. Regarding current trading prices, DXR is priced at $10.38, while LMAT trades at $102.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas LMAT's P/E ratio is 39.88. In terms of profitability, DXR's ROE is +0.22%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, DXR is less volatile compared to LMAT. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check LMAT's competition here
DXR vs XRAY Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, XRAY has a market cap of 2.3B. Regarding current trading prices, DXR is priced at $10.38, while XRAY trades at $11.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas XRAY's P/E ratio is 8.15. In terms of profitability, DXR's ROE is +0.22%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, DXR is less volatile compared to XRAY. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check XRAY's competition here
DXR vs PLSE Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, PLSE has a market cap of 2B. Regarding current trading prices, DXR is priced at $10.38, while PLSE trades at $29.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas PLSE's P/E ratio is -26.55. In terms of profitability, DXR's ROE is +0.22%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, DXR is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check PLSE's competition here
DXR vs ATRC Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, ATRC has a market cap of 1.6B. Regarding current trading prices, DXR is priced at $10.38, while ATRC trades at $31.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas ATRC's P/E ratio is 987.27. In terms of profitability, DXR's ROE is +0.22%, compared to ATRC's ROE of -0.01%. Regarding short-term risk, DXR is less volatile compared to ATRC. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ATRC's competition here
DXR vs KMTS Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, KMTS has a market cap of 1.6B. Regarding current trading prices, DXR is priced at $10.38, while KMTS trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas KMTS's P/E ratio is -9.84. In terms of profitability, DXR's ROE is +0.22%, compared to KMTS's ROE of -0.69%. Regarding short-term risk, DXR is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check KMTS's competition here
DXR vs STAA Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, STAA has a market cap of 1.4B. Regarding current trading prices, DXR is priced at $10.38, while STAA trades at $27.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas STAA's P/E ratio is 48.75. In terms of profitability, DXR's ROE is +0.22%, compared to STAA's ROE of -0.06%. Regarding short-term risk, DXR is less volatile compared to STAA. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check STAA's competition here
DXR vs BLFS Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, BLFS has a market cap of 1.4B. Regarding current trading prices, DXR is priced at $10.38, while BLFS trades at $28.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas BLFS's P/E ratio is -133.00. In terms of profitability, DXR's ROE is +0.22%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, DXR is less volatile compared to BLFS. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check BLFS's competition here
DXR vs QDEL Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, QDEL has a market cap of 1.2B. Regarding current trading prices, DXR is priced at $10.38, while QDEL trades at $18.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas QDEL's P/E ratio is 13.62. In terms of profitability, DXR's ROE is +0.22%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, DXR is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check QDEL's competition here
DXR vs AZTA Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, AZTA has a market cap of 1.2B. Regarding current trading prices, DXR is priced at $10.38, while AZTA trades at $25.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas AZTA's P/E ratio is 57.42. In terms of profitability, DXR's ROE is +0.22%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, DXR is less volatile compared to AZTA. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check AZTA's competition here
DXR vs ATRI Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, DXR is priced at $10.38, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas ATRI's P/E ratio is 64.50. In terms of profitability, DXR's ROE is +0.22%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, DXR is less volatile compared to ATRI. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ATRI's competition here
DXR vs NNNN Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, NNNN has a market cap of 557.4M. Regarding current trading prices, DXR is priced at $10.38, while NNNN trades at $12.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas NNNN's P/E ratio is 183.53. In terms of profitability, DXR's ROE is +0.22%, compared to NNNN's ROE of +0.23%. Regarding short-term risk, DXR is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check NNNN's competition here
DXR vs ANGO Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, ANGO has a market cap of 540.9M. Regarding current trading prices, DXR is priced at $10.38, while ANGO trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas ANGO's P/E ratio is -37.40. In terms of profitability, DXR's ROE is +0.22%, compared to ANGO's ROE of -0.18%. Regarding short-term risk, DXR is less volatile compared to ANGO. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ANGO's competition here
DXR vs OSUR Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, OSUR has a market cap of 299.5M. Regarding current trading prices, DXR is priced at $10.38, while OSUR trades at $4.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas OSUR's P/E ratio is -5.24. In terms of profitability, DXR's ROE is +0.22%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, DXR is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check OSUR's competition here
DXR vs UTMD Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, UTMD has a market cap of 231.7M. Regarding current trading prices, DXR is priced at $10.38, while UTMD trades at $72.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas UTMD's P/E ratio is 21.53. In terms of profitability, DXR's ROE is +0.22%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, DXR is less volatile compared to UTMD. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check UTMD's competition here
DXR vs SMTI Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, SMTI has a market cap of 227.6M. Regarding current trading prices, DXR is priced at $10.38, while SMTI trades at $24.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas SMTI's P/E ratio is -414.00. In terms of profitability, DXR's ROE is +0.22%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, DXR is less volatile compared to SMTI. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check SMTI's competition here
DXR vs KRMD Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, KRMD has a market cap of 206.2M. Regarding current trading prices, DXR is priced at $10.38, while KRMD trades at $4.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas KRMD's P/E ratio is -112.25. In terms of profitability, DXR's ROE is +0.22%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, DXR is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check KRMD's competition here
DXR vs INFU Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, INFU has a market cap of 205M. Regarding current trading prices, DXR is priced at $10.38, while INFU trades at $10.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas INFU's P/E ratio is 26.74. In terms of profitability, DXR's ROE is +0.22%, compared to INFU's ROE of +0.14%. Regarding short-term risk, DXR is less volatile compared to INFU. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check INFU's competition here
DXR vs PDEX Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, PDEX has a market cap of 195.8M. Regarding current trading prices, DXR is priced at $10.38, while PDEX trades at $61.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas PDEX's P/E ratio is 21.60. In terms of profitability, DXR's ROE is +0.22%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, DXR is less volatile compared to PDEX. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check PDEX's competition here
DXR vs MBOT Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, MBOT has a market cap of 87M. Regarding current trading prices, DXR is priced at $10.38, while MBOT trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas MBOT's P/E ratio is -7.35. In terms of profitability, DXR's ROE is +0.22%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, DXR is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check MBOT's competition here
DXR vs AKYA Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, DXR is priced at $10.38, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas AKYA's P/E ratio is -1.34. In terms of profitability, DXR's ROE is +0.22%, compared to AKYA's ROE of -27.96%. Regarding short-term risk, DXR and AKYA have similar daily volatility (0.00).Check AKYA's competition here
DXR vs STSS Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, STSS has a market cap of 51.2M. Regarding current trading prices, DXR is priced at $10.38, while STSS trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas STSS's P/E ratio is -0.02. In terms of profitability, DXR's ROE is +0.22%, compared to STSS's ROE of -1.66%. Regarding short-term risk, DXR is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check STSS's competition here
DXR vs OMIC Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, DXR is priced at $10.38, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas OMIC's P/E ratio is -0.58. In terms of profitability, DXR's ROE is +0.22%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, DXR is less volatile compared to OMIC. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check OMIC's competition here
DXR vs IGAP Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, DXR is priced at $10.38, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas IGAP's P/E ratio is -10.52. In terms of profitability, DXR's ROE is +0.22%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, DXR is less volatile compared to IGAP. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check IGAP's competition here
DXR vs POCI Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, POCI has a market cap of 39.1M. Regarding current trading prices, DXR is priced at $10.38, while POCI trades at $5.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas POCI's P/E ratio is -7.03. In terms of profitability, DXR's ROE is +0.22%, compared to POCI's ROE of -0.37%. Regarding short-term risk, DXR is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check POCI's competition here
DXR vs NEPH Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, NEPH has a market cap of 36.9M. Regarding current trading prices, DXR is priced at $10.38, while NEPH trades at $3.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas NEPH's P/E ratio is 48.57. In terms of profitability, DXR's ROE is +0.22%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, DXR is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check NEPH's competition here
DXR vs MLSS Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, MLSS has a market cap of 30.3M. Regarding current trading prices, DXR is priced at $10.38, while MLSS trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas MLSS's P/E ratio is -5.70. In terms of profitability, DXR's ROE is +0.22%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, DXR is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check MLSS's competition here
DXR vs SDC Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, DXR is priced at $10.38, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas SDC's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.22%, compared to SDC's ROE of -1.96%. Regarding short-term risk, DXR is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check SDC's competition here
DXR vs HBIO Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, HBIO has a market cap of 27.7M. Regarding current trading prices, DXR is priced at $10.38, while HBIO trades at $6.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas HBIO's P/E ratio is -17.08. In terms of profitability, DXR's ROE is +0.22%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, DXR is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check HBIO's competition here
DXR vs IVC Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, DXR is priced at $10.38, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas IVC's P/E ratio is -0.79. In terms of profitability, DXR's ROE is +0.22%, compared to IVC's ROE of -0.46%. Regarding short-term risk, DXR is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check IVC's competition here
DXR vs RVP Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, RVP has a market cap of 21.9M. Regarding current trading prices, DXR is priced at $10.38, while RVP trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas RVP's P/E ratio is -2.21. In terms of profitability, DXR's ROE is +0.22%, compared to RVP's ROE of -0.08%. Regarding short-term risk, DXR is less volatile compared to RVP. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check RVP's competition here
DXR vs ARTC Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, ARTC has a market cap of 16.1M. Regarding current trading prices, DXR is priced at $10.38, while ARTC trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas ARTC's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to ARTC's ROE of N/A. Regarding short-term risk, DXR and ARTC have similar daily volatility (0.00).Check ARTC's competition here
DXR vs RGNT Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, RGNT has a market cap of 15.9M. Regarding current trading prices, DXR is priced at $10.38, while RGNT trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas RGNT's P/E ratio is -0.17. In terms of profitability, DXR's ROE is +0.22%, compared to RGNT's ROE of N/A. Regarding short-term risk, DXR is less volatile compared to RGNT. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check RGNT's competition here
DXR vs ZJYL Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, ZJYL has a market cap of 15.3M. Regarding current trading prices, DXR is priced at $10.38, while ZJYL trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas ZJYL's P/E ratio is 12.25. In terms of profitability, DXR's ROE is +0.22%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, DXR is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ZJYL's competition here
DXR vs FEMY Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, FEMY has a market cap of 12.6M. Regarding current trading prices, DXR is priced at $10.38, while FEMY trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas FEMY's P/E ratio is -11.52. In terms of profitability, DXR's ROE is +0.22%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, DXR is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check FEMY's competition here
DXR vs NXGL Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, NXGL has a market cap of 5.2M. Regarding current trading prices, DXR is priced at $10.38, while NXGL trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas NXGL's P/E ratio is -1.45. In terms of profitability, DXR's ROE is +0.22%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, DXR is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check NXGL's competition here
DXR vs NSTG Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, DXR is priced at $10.38, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas NSTG's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.22%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, DXR is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check NSTG's competition here
DXR vs POAI Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, DXR is priced at $10.38, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas POAI's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.22%, compared to POAI's ROE of -107.05%. Regarding short-term risk, DXR is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check POAI's competition here
DXR vs LUCY Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, LUCY has a market cap of 3M. Regarding current trading prices, DXR is priced at $10.38, while LUCY trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas LUCY's P/E ratio is -0.45. In terms of profitability, DXR's ROE is +0.22%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, DXR is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check LUCY's competition here
DXR vs MHUA Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, DXR is priced at $10.38, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas MHUA's P/E ratio is 0.25. In terms of profitability, DXR's ROE is +0.22%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, DXR and MHUA have similar daily volatility (0.00).Check MHUA's competition here
DXR vs NXGLW Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, NXGLW has a market cap of 2.1M. Regarding current trading prices, DXR is priced at $10.38, while NXGLW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas NXGLW's P/E ratio is -0.07. In terms of profitability, DXR's ROE is +0.22%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, DXR and NXGLW have similar daily volatility (0.00).Check NXGLW's competition here
DXR vs GMVD Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, DXR is priced at $10.38, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas GMVD's P/E ratio is -0.01. In terms of profitability, DXR's ROE is +0.22%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, DXR is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check GMVD's competition here
DXR vs GMVDW Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, DXR is priced at $10.38, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas GMVDW's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, DXR is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check GMVDW's competition here
DXR vs AVGR Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, DXR is priced at $10.38, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas AVGR's P/E ratio is -0.05. In terms of profitability, DXR's ROE is +0.22%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, DXR is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check AVGR's competition here
DXR vs LUCYW Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, DXR is priced at $10.38, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas LUCYW's P/E ratio is -0.00. In terms of profitability, DXR's ROE is +0.22%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, DXR is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check LUCYW's competition here
DXR vs GCTK Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, GCTK has a market cap of 181.6K. Regarding current trading prices, DXR is priced at $10.38, while GCTK trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas GCTK's P/E ratio is -0.02. In terms of profitability, DXR's ROE is +0.22%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, DXR is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check GCTK's competition here
DXR vs IIN Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, IIN has a market cap of 0. Regarding current trading prices, DXR is priced at $10.38, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas IIN's P/E ratio is 226.45. In terms of profitability, DXR's ROE is +0.22%, compared to IIN's ROE of -0.00%. Regarding short-term risk, DXR is less volatile compared to IIN. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check IIN's competition here
DXR vs IVTY Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, DXR is priced at $10.38, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas IVTY's P/E ratio is -3.80. In terms of profitability, DXR's ROE is +0.22%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, DXR and IVTY have similar daily volatility (0.00).Check IVTY's competition here
DXR vs ALOG Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, DXR is priced at $10.38, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas ALOG's P/E ratio is 40.93. In terms of profitability, DXR's ROE is +0.22%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, DXR and ALOG have similar daily volatility (0.00).Check ALOG's competition here
DXR vs HRC Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, HRC has a market cap of 0. Regarding current trading prices, DXR is priced at $10.38, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas HRC's P/E ratio is 41.92. In terms of profitability, DXR's ROE is +0.22%, compared to HRC's ROE of +0.14%. Regarding short-term risk, DXR is less volatile compared to HRC. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check HRC's competition here
DXR vs APR Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, APR has a market cap of 0. Regarding current trading prices, DXR is priced at $10.38, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas APR's P/E ratio is 22.59. In terms of profitability, DXR's ROE is +0.22%, compared to APR's ROE of +9.81%. Regarding short-term risk, DXR is less volatile compared to APR. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check APR's competition here
DXR vs ATRS Comparison July 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 52.3M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, DXR is priced at $10.38, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 27.15, whereas ATRS's P/E ratio is 14.95. In terms of profitability, DXR's ROE is +0.22%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, DXR is less volatile compared to ATRS. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check ATRS's competition here